{"DataElement":{"publicId":"2200404","version":"1","preferredName":"Prior Investigational Therapies Administered Ind-2","preferredDefinition":"the yes/no indicator whether prior investigational therapies were administered.","longName":"PRI_INVEST_ADM_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2200403","version":"1","preferredName":"Prior Investigational Therapeutic Procedure Administered","preferredDefinition":"information related to the prior investigational therapies being administered.","longName":"PRIOR_INVESTTX_ADMIN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3440626","version":"1","preferredName":"Prior Investigational Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:In the process of being studied; experimental.  (NCI):An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C28041:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Investigational","conceptCode":"C28041","definition":"In the process of being studied; experimental.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE222540-1323-83B9-E040-BB89AD435B86","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-04-20","modifiedBy":"ONEDATA","dateModified":"2012-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F11E1A98-D758-67E3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]},{"publicId":"2552643","version":"1","longName":"Training Class Examples","context":"Training","ClassificationSchemeItems":[{"publicId":"3637837","version":"1","longName":"Training","context":"Training"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104894","version":"1","longName":"GOG-0231D","context":"NRG"},{"publicId":"4104941","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000705","version":"1","longName":"GOG-0281","context":"NRG"}]}],"AlternateNames":[{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"SWOG","type":"USED_BY","context":"SWOG"},{"name":"PINVDRUG","type":"OID, SWOG","context":"SWOG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"PRI_INVEST_ADM_IND2","type":"USED_BY","context":"NRG"},{"name":"PRI_INVEST_ADM_IND2","type":"USED_BY","context":"Alliance"},{"name":"PRI_INVEST_ADM_IND2","type":"USED_BY","context":"CITN"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Prior investigational therapy?","type":"Preferred Question Text","description":"Prior investigational therapy?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Has the patient received other investigational agents within the past 14 days?","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Has the patient had any investigational agents within 30 days before randomization?","url":null,"context":"CTEP"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Has the patient taken any investigational product within the past 30 days?","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Patients must not have had administration of any investigational agents within 30 days before study entry?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Has the patient had any investigational product within the past 30 days?","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Has the patient had prior therapy with MLN8237 or taken part in a study of an investigational compound or device within 4 weeks of entering this study?","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Prior investigational agents?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"At least 4 weeks from last dose of prior investigational therapy","url":null,"context":"CTEP"},{"name":"AECC Text 1","type":"Alternate Question Text","description":"Is patient receiving any other investigational agents?","url":null,"context":"AECC"},{"name":"ECOG CRF 1","type":"Alternate Question Text","description":"Did the patient receive any other investigational agent?","url":null,"context":"ECOG-ACRIN"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"At least 4 weeks from last dose of prior investigational therapy with full recovery from toxicities","url":null,"context":"CTEP"},{"name":"Investigational drug","type":"Alternate Question Text","description":"Investigational drug","url":null,"context":"SWOG"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Did the patient have exposure to an investigational product within 30 days or five half lives (whichever is longer) prior to randomization?","url":null,"context":"CTEP"},{"name":"CRF Text10","type":"Alternate Question Text","description":"Patients treated on any other therapeutic clinical protocols within 30 days prior to step 2 registration","url":null,"context":"NRG"},{"name":"CRF Text 11","type":"Alternate Question Text","description":"Did the patient have exposure to an investigational product within 30 days or five half lives (whichever is longer)?","url":null,"context":"CTEP"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Has the patient had any other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib or standard of care agent?","url":null,"context":"NRG"},{"name":"CRF Text 13","type":"Alternate Question Text","description":"Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Was other investigational agent administered within 14 days of the start of this trial or within 30 days of any dose of bortezomib?","url":null,"context":"CTEP"},{"name":"ALT 1","type":"Alternate Question Text","description":"Has the patient received other investigational agents prior to enrollment?","url":null,"context":"ECOG-ACRIN"},{"name":"CITN","type":"Alternate Question Text","description":"At least 4 weeks from last dose of prior investigational therapy with recovery to meet baseline eligibility criteria.","url":null,"context":"CITN"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Prior use of investigational agent","url":null,"context":"Alliance"},{"name":"COG CRF Text 14","type":"Alternate Question Text","description":"Is patient currently receiving another investigational drug?","url":null,"context":"CTEP"},{"name":"CRF_Text_14","type":"Alternate Question Text","description":"Has the patient had prior treatment with an investigational compound being tested in this study (e.g., PARP inhibitor)?","url":null,"context":"CTEP"},{"name":"CRF Text15","type":"Alternate Question Text","description":"Prior treatment with any other type of investigational agent?","url":null,"context":"Alliance"},{"name":"CRF Text 14","type":"Alternate Question Text","description":"Has the patient had prior treatment with an investigational compound being tested in this study (e.g., PARP inhibitor, anti-PD-1, anti-PD-L1, or anti-PD-L2)?","url":null,"context":"CTEP"},{"name":"CRF Text16","type":"Alternate Question Text","description":"Prior investigational agent for malignancy?","url":null,"context":"Alliance"},{"name":"COG CRF TEXT 15","type":"Alternate Question Text","description":"Has patient received any other investigational agents within 4 weeks prior to study enrollment?","url":null,"context":"COG"},{"name":"CRF Text18","type":"Alternate Question Text","description":"Was all treatment administered and completed in less than or equal to 14 days?","url":null,"context":"Alliance"},{"name":"CRF Text17","type":"Alternate Question Text","description":"Was all treatment administered and completed in â‰¤ 14 days?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Did patient, who received a PARP inhibitor maintenance therapy in the frontline setting, have at least one other chemotherapy for recurrence prior to enrolling on this trial?","url":null,"context":"NRG"},{"name":"CRF Text19","type":"Alternate Question Text","description":"Any current or planned treatment with any other investigational agents for GBM or lower grade glioma?","url":null,"context":"NRG"},{"name":"CRF TEXT 20","type":"Alternate Question Text","description":"Any current or planned treatment with any other investigational agents for the study cancer?","url":null,"context":"NRG"},{"name":"CRF Text21","type":"Alternate Question Text","description":"Has the patient received any prior investigational therapy?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Did the patient use any investigational product within 30 days prior to study entry?","url":null,"context":"NRG"},{"name":"CRF Text22","type":"Alternate Question Text","description":"Prior treatment with any other investigational agent?","url":null,"context":"Alliance"},{"name":"COG CRF Text 16","type":"Alternate Question Text","description":"Has patient received  any investigational agent  or any other anticancer therapy at least 4 weeks prior to planned start day of DAY101?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has patient received  any investigational agent at least 4 weeks prior to planned start day of DAY101?","url":null,"context":"COG"},{"name":"COG CRF Text 35","type":"Alternate Question Text","description":"Has patient received  any investigational agent for at least 14 days prior to planned start day of DAY101?*","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Has the patient received prior investigational agents within 4 weeks of registration?","url":null,"context":"NRG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Has patient received  any investigational agent  or any other anticancer therapy for at least 14 days prior to planned start day of DAY101?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_4","type":"Alternate Question Text","description":"Has the patient received prior PARP-inhibitors?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Was prior PARP inhibitor therapy given as the last line of therapy prior to initiation of this trial?","url":null,"context":"NRG"},{"name":"COG CRF Text 21","type":"Alternate Question Text","description":"Has patient received  any investigational agent  or any other anticancer therapy for at least 14 days prior to planned start day of DAY101?","url":null,"context":"COG"},{"name":"COG CRF Text 36","type":"Alternate Question Text","description":"Has patient received any investigational agent for at least 14 days prior to planned start day of DAY101?","url":null,"context":"COG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Has the patient received prior PARP inhibitor?","url":null,"context":"NRG"},{"name":"COG CRF Text 37","type":"Alternate Question Text","description":"Is the patient receiving any other investigational agent not defined within this protocol?","url":null,"context":"COG"},{"name":"NRG CRF Text 2","type":"Alternate Question Text","description":"Has the patient used  any investigational product within 30 days prior to randomization?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_3","type":"Alternate Question Text","description":"Has the patient received, or is the patient receiving, an investigational medicinal product (IMP) or other systemic anti-cancer treatment (including chemotherapy, immunotherapy, targeted therapy, biologic therapy, tumor embolization, or monoclonal antibodies) within 4 weeks prior to registration, or within a period during which the IMP or systemic target treatment has not been cleared from the body (e.g., a period of 5 'half-lives'), whichever is longer?","url":null,"context":"NRG"},{"name":"NRG CRF Text 3","type":"Alternate Question Text","description":"Has the patient used any investigational product within 30 days prior to study entry?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_5","type":"Alternate Question Text","description":"Did the patient use any investigational product within 30 days prior to pre-entry/Step 1?","url":null,"context":"NRG"},{"name":"CRF Text23","type":"Alternate Question Text","description":"Prior targeted (non-mAb) or investigational agents?","url":null,"context":"Alliance"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F157111D-2A84-7233-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-02","modifiedBy":"ZHWENDY","dateModified":"2024-01-18","changeDescription":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"11.09.2023 Added AQT per request ticket CADSR0003062_mmt\r\n2022.12.21 AQT added per ticket request CADSR0001812. ak 11/9/22 added AQT for ticket number CADSR0001669 cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}